Pharmaforfun

A critical topic in antimicrobial therapy is the management of infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA). This post outlines the key antibiotic classes and agents used for MRSA coverage.

1. Glycopeptides

This class is a cornerstone for treating serious MRSA infections.

✅Vancomycin (IV): Considered the gold standard for invasive MRSA infections, including bacteremia, pneumonia, endocarditis, meningitis, and osteomyelitis.
It is a bactericidal agent. Important considerations include the need for therapeutic drug monitoring to minimize the risks of nephrotoxicity and ototoxicity,
🔴 as well as the potential for Red Man Syndrome during infusion.

✅Teicoplanin: Widely approved in Europe and Asia, it is used for complicated skin and soft tissue infections (cSSTI) and bone and joint infections. Its advantages over vancomycin include a lower risk of nephrotoxicity and the absence of Red Man Syndrome.

2. Lipopeptides

✅Daptomycin (IV): This agent is a primary choice for MRSA bacteremia and right-sided endocarditis. It is also effective for complicated skin and soft tissue infections (cSSTI).
🔴A crucial contraindication is that it is ineffective for pneumonia, as pulmonary surfactant inactivates the drug.

3. Oxazolidinones

✅Linezolid (IV/PO): An excellent option for cSSTI and hospital-acquired/ventilator-associated pneumonia (HAP/VAP). Its excellent oral bioavailability makes it a key agent for IV-to-oral switch therapy.

🔴 It is bacteriostatic against staphylococci, which is why it is not a first-line agent for endocarditis, where a bactericidal effect is preferred.

4. Glycylcyclines

✅Tigecycline (IV): A broad-spectrum agent approved for cSSTI and intra-abdominal infections (IAI), typically used when other options are limited.

🔴 Its pharmacokinetics are characterized by a high volume of distribution, leading to extensive tissue pe*******on but low serum levels. Consequently, it should be avoided for bacteremia.

🔴 Furthermore, due to poor urinary excretion, it is not indicated for urinary tract infections (UTIs) and should be avoided for that purpose.

Welcome back to our antibiotic series! In this second episode, we're focusing on a critical and often confusing area: antipseudomonal coverage. A common pitfall, especially early in one's career, is to assume all antibiotics within a class have identical coverage. I recall when starting my job treating every antibiotic in a class as interchangeable, overlooking the important exceptions. Today, we'll highlight those key exceptions across several major antibiotic classes.😊

Why Does Antipseudomonal Coverage Matter?

Pseudomonas aeruginosa is notoriously resistant to many drugs and is a major cause of severe healthcare-associated infections. Antipseudomonal coverage is essential for managing

✅Hospital-Acquired Infections: Especially in critically ill patients.

✅Ventilator-Associated Pneumonia (VAP) and Hospital-Acquired Pneumonia (HAP)

✅Catheter-Associated Urinary Tract Infections (CAUTI)

✅Central Line-Associated Bloodstream Infections (CLABSI)

✅Complex Skin and Soft Tissue Infections (e.g., in burn wounds or diabetic foot infections)

✅Bone Infections (Osteomyelitis), particularly in the spine or following trauma/surgery.

Now, let's look at which antibiotics provide this crucial coverage.

Antipseudomonal Coverage by Class:

1. Penicillins with β-Lactamase Inhibitors (BLI)

Within this group, only specific combinations
are effective.
✅Ticarcillin-clavulanate ( not in Egypt yet) a
✅Piperacillin-tazobactam
are the key players with reliable activity against Pseudomonas.

2. Cephalosporins
Out of the entire cephalosporin family, only three agents have significant antipseudomonal activity:

✅Ceftazidime

✅Cefepime

✅Cefoperazone

Among these, Cefepime is the most commonly used beta-lactam for targeting P. aeruginosa.

3. Fluoroquinolones

This class offers valuable oral options. Currently,
✅ciprofloxacin
✅levofloxacin
are the only oral agents used for quinolone-sensitive Pseudomonas. However, ciprofloxacin is generally preferred over levofloxacin due to a higher risk of emergent resistance with the latter.

🔴It is important to note that moxifloxacin does not have reliable antipseudomonal coverage.

4. Carbapenems
Most carbapenems are powerful weapons against Pseudomonas. This includes:

✅Meropenem

✅Imipenem

✅Doripenem

Meropenem is often preferred over imipenem because the latter has a higher propensity to induce resistance during treatment.

🔴A critical exception in this class is ertapenem, which has no antipseudomonal activity.

As clinical pharmacists, we hold a significant responsibility in all matters related to antibiotics and infectious diseases. This field is dense with information and intricate details that can be challenging to memorize. Because we are consistently asked about antibiotic coverage and the most suitable agent for each case, I have decided to launch an antibiotic series. In each episode, we will demystify the spectrum of a different antibiotic.

Today's Episode: Atypical Bacterial Coverage in Community Acquired Pneumonia (CAP) ✨

We will focus on the "atypical" bacteria, key causative agents of Community Acquired Pneumonia (CAP). These pathogens include:

✅Mycoplasma pneumoniae

✅Chlamydia pneumoniae (now Chlamydophila pneumoniae)

✅Legionella pneumophila

A common clinical error in CAP management I always see during my job is neglecting this atypical coverage and relying solely on beta-lactam antibiotics.

To understand why this is a problem, let's review the common pathogens in CAP, which are broadly categorized as follows:

"Typical" Bacteria:

✅Streptococcus pneumoniae (the most common)

✅Haemophilus influenzae

✅Moraxella catarrhalis

And a typical Bacteria which I have mentioned earlier.
Here is the critical point: Beta-lactam antibiotics (e.g., penicillins like amoxicillin or cephalosporins like ceftriaxone) are excellent against typical bacteria. However, they have no reliable activity against atypical pathogens. This is because atypicals lack a traditional cell wall, the very target of beta-lactam drugs.

Therefore, ensuring empiric regimens have adequate atypical coverage is fundamental to effective CAP management ☺️

النهاردة هنتكلم شوية عن الكاربيمازول من أهم الأدوية اللى بتعالج فرط نشاط الغدة الدرقية و كمان فيه أزمة كبيرة دلوقتى في توفيره لأنه ناقص، كتير من الروشتات اللى بيبقي مكتوب فيها كاربيمازول بيبقي مكتوب ممكن بال 8 أو 10 حبة في اليوم وممكن توصل 12 حبة كمان ودا لأنه التركيز الوحيد المتوفر في السوق هو ال 5 mg بس ف دا يخلينا نسأل نفسنا ليه مفيش أدوية فيها تركيز أكبر من الكاربيمازول في السوق عشان مشكلة ال adherence و ال compliance للمريض خصوصا انى دورت ولقيت أنه مفيش اي سبب علمي أو صيدلانى يمنع وجود حاجة زى كده
لو حد عنده إجابة ياريت يشاركنا بيها فى الكومنتات.

Today's post is about a question that always confuses me regarding carbimazole, but first here is some information about carbimazole
Carbimazole is a medicine used to treat an overactive thyroid (hyperthyroidism).
dosage:
Adult: Initially, 15-60 mg daily in 2-3 divided doses, titrate dose against thyroid function until euthyroidism is achieved. Maintenance: 5-15 mg daily (may be given as a single dose), adjust dose as needed to maintain euthyroid state. Blocking-replacement regimen: Initially, 20-60 mg daily in combination with levothyroxine. Treatment duration: 6-18 months.
Child: 3-17 years Initially, 15 mg daily adjusted according to response
so after we knew the dose of carbimazole, i didn't find any product in the Egyptian market containing carbimazole higher than 5 mg per tablet so according to the dose, patients may need to take up to 12 tablets per day which is a real problem for patient adherence and compliance.
I saw many prescriptions containing this number of tablets and I searched very much for the reason why there's no drug containing higher dose of carbimazole and if it related to any Pharmaceutical cause but I didn't find any answer so if any one have any answer, you can share it with me and for the pharmacist from the other countries can you tell me if there's drugs containing crabimazole other than 5mg.